- Home
- GDTC vs CVKD Comparison
GDTC vs CVKD Comparison
Compare GDTC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- CVKD
- Stock Information
- Founded
- GDTC 2018
- CVKD 2022
- Country
- GDTC Singapore
- CVKD United States
- Employees
- GDTC N/A
- CVKD N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- GDTC Health Care
- CVKD Health Care
- Exchange
- GDTC Nasdaq
- CVKD Nasdaq
- Market Cap
- GDTC 28.0M
- CVKD 29.5M
- IPO Year
- GDTC 2023
- CVKD 2023
- Fundamental
- Price
- GDTC $2.07
- CVKD $12.13
- Analyst Decision
- GDTC Buy
- CVKD Strong Buy
- Analyst Count
- GDTC 1
- CVKD 1
- Target Price
- GDTC $5.00
- CVKD $32.00
- AVG Volume (30 Days)
- GDTC 6.6K
- CVKD 36.2K
- Earning Date
- GDTC 01-01-0001
- CVKD 08-06-2025
- Dividend Yield
- GDTC N/A
- CVKD N/A
- EPS Growth
- GDTC N/A
- CVKD N/A
- EPS
- GDTC N/A
- CVKD N/A
- Revenue
- GDTC $368,838.00
- CVKD N/A
- Revenue This Year
- GDTC $5.37
- CVKD N/A
- Revenue Next Year
- GDTC N/A
- CVKD N/A
- P/E Ratio
- GDTC N/A
- CVKD N/A
- Revenue Growth
- GDTC N/A
- CVKD N/A
- 52 Week Low
- GDTC $1.20
- CVKD $5.70
- 52 Week High
- GDTC $4.05
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- GDTC 45.73
- CVKD 49.98
- Support Level
- GDTC $2.12
- CVKD $11.00
- Resistance Level
- GDTC $2.22
- CVKD $13.56
- Average True Range (ATR)
- GDTC 0.09
- CVKD 1.15
- MACD
- GDTC -0.00
- CVKD 0.25
- Stochastic Oscillator
- GDTC 28.57
- CVKD 80.97
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.